menu
    • menu

    Company profile for Ryvu Therapeutics

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology. Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment. The company is headquartered in Kraków, Poland...
    Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology. Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment. The company is headquartered in Kraków, Poland. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ryvu TherapeuticsPoland Flag
    Country
    Country
    Poland
    Address
    Address
    Bobrzyńskiego 14 30-348 Kraków, Poland
    Telephone
    Telephone
    +48 12 297 46 90
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ryvu.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ryvutx/about/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/RyvuTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AACR Annual meeting

    AACR Annual meeting

    Not Confirmed

    envelop Contact Supplier

    AACR Annual meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ryvu Therapeutics Unveils ONCO Prime Data at 2026 AACR
    Ryvu Therapeutics Unveils ONCO Prime Data at 2026 AACR

    19 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-19/ryvu-therapeutics-to-present-preclinical-data-on-the-onco-prime-platform-at-the-2026-aacr-annual-meeting-and-announces-pero-grant-agreement

    PHARMIWEB
    19 Mar 2026
    Share Share
    Ryvu Therapeutics Unveils Romaciclib Data At (ASH) 2025 Meeting
    Ryvu Therapeutics Unveils Romaciclib Data At (ASH) 2025 Meeting

    11 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-11/ryvu-therapeutics-presents-new-clinical-data-from-river-81-and-potami-61-studies-of-romaciclib-rvu120-at-the-2025-american-society-of-hematology-as

    PHARMIWEB
    11 Dec 2025
    Share Share
    Ryvu Therapeutics Presents Abstracts On Romaciclib
    Ryvu Therapeutics Presents Abstracts On Romaciclib

    05 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-05/ryvu-therapeutics-announces-three-abstracts-on-romaciclib-rvu120-and-one-abstract-on-dapolsertib-men1703-at-the-2025-american-society-of-hematolog

    PHARMIWEB
    05 Nov 2025
    Share Share
    Ryvu Therapeutics Supports BioNTech Clinical Trials in Poland
    Ryvu Therapeutics Supports BioNTech Clinical Trials in Poland

    03 Sep 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/ryvu-therapeutics-to-support-clinical-trials-for-biontech-in-poland/

    CONTRACTPHARMA
    03 Sep 2025
    Share Share
    Ryvu Therapeutics reorganizes to extend cash runway for RVU120
    Ryvu Therapeutics reorganizes to extend cash runway for RVU120

    25 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ryvu-therapeutics-announces-strategic-reorganization-to-extend-the-cash-runway-for-the-development-of-rvu120-and-the-preclinical-pipeline-302384585.html

    PR NEWSWIRE
    25 Feb 2025
    Share Share
    Ryvu Therapeutics provides an update on RVU120 Phase II program
    Ryvu Therapeutics provides an update on RVU120 Phase II program

    12 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-302330063.html

    PR NEWSWIRE
    12 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search